कृपया अन्य खोज का प्रयास करें
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Rolf A. Classon | 78 | 2014 | Independent Director |
Jack L. Stahl | 70 | 2014 | Independent Lead Director |
Gregory T. Lucier | 59 | 2015 | Independent Director |
Edward R. Robinson | - | 2015 | Member of Advisory Board |
Donald Eugene Morel | 65 | 2015 | Independent Director |
Michael J. Buckley | 62 | 2015 | Member of Advisory Board |
Carolyn R. Bertozzi | 56 | 2015 | Member of Scientfic & Advisory Board |
Barry C. Buckland | 75 | 2015 | Member of Advisory Board |
Daniel R. Marshak | 66 | 2015 | Member of Advisory Board |
J. Martin Carroll | 74 | 2015 | Independent Director |
Matthew R. Stober | 56 | - | Member of the Biologics Advisory Board |
Steven K. Barg | 60 | 2023 | Independent Director |
David E. Schaffer | 54 | 2019 | Member of the Biologics Advisory Board |
Stephanie Smith Okey | 63 | 2023 | Independent Director |
Michael J. Barber | 63 | 2021 | Independent Director |
Michelle R. Ryan | 57 | 2023 | Independent Director |
Frank A. D'Amelio | 66 | 2023 | Independent Director |
John J. Greisch | 69 | 2018 | Executive Chairman of the Board |
Alessandro Maselli | 52 | 2016 | President, CEO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है